Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator

Tissue Polypeptide Antigen and Tissue Polypeptide Specific Antigen in Primary Breast Cancer. Evaluation in Serum and Tutmour Tissue

“…tissue polypeptide antigen (TPA IRMA) and tissue polypeptide antigen (TPA-M IRMA) provide closely associated results; although their absolute values are in part different, they are expected to provide overlapping clinical Information; 2. tissue polypeptide specific antigen is associated with tissue polypeptide antigen (TPA-M IRMA) and tissue polypeptide antigen (TPA IRMA); the relationship between the tumour markers and other biological quantities are in the same direction. Even accepting that tissue polypeptide specific antigen could measure a tissue polypeptide antigen-specific epitope, it is evident that it also measures cytokeratin fragments in a quantitatively significant manner; 3. from a practical point of view, cytosol and serum should be considered independent biological fluids äs far äs tissue polypeptide antigen (TPA IRMA) and tissue polypeptide specific antigen determinations are concerned; 4. the direct association between cytosol levels of tissue polypeptide antigen (TPA IRMA), tissue polypeptide antigen (TPA-M IRMA), and tissue polypeptide specific antigen and receptor Status represents a potential association between the mafkers and prognosis, in agreement with previous fmdings of our group concerning cytosolic tissue polypeptide antigen (14)(15)(16).…”

“…The problem should be evaluated from the point of view of the clinical application, to assess whether the markers provide similar or different Information. This point is of relevance in breast cancer, since both serum and cytosol tissue polypeptide antigen (TPA IRMA) levels showed a clear clinical usefulness (10,(13)(14)(15)(16).…”

“…Conversely, a high cytosol tissue polypeptide antigen (TPA IRMA) level was shown to be a powerful, independent, favourable prognostic indicator (14)(15)(16).…”

PS2 in breast cancer – alternative or complementary tool to steroid receptor status? Evaluation of 446 cases

“…In the examined patient series, the most effective pS2 value capable of discriminating between good and poor prognosis was 4 ng mg-' cytosolic protein for both relapse-free survival (RFS) and overall survival (OS) (Figure 1). The same method for the identification of the best cutoff point has been previously used for the evaluation of the prognostic value of the other parameters studied in the present investigation (Gion et al, 1993). The relapse-free survival (RFS) and the overall survival (OS) were calculated by the Kaplan-Meier product limit method.…”

“…The two latter cytoplasmic proteins are prognostic indicators in patients with breast cancer (Spyratos et al, 1989, Gion et al, 1993.…”